|Summary sheet: LSZ|
|Common names||LSZ, LA-SS-Az, Diazedine, Lambda|
|Substitutive name||Lysergic acid 2,4-dimethylazetidide|
|Routes of Administration|
In the 2000s, a team led by David E. Nichols at Purdue University set to develop a rigid analog of LSD with the diethylamide group constrained into an azetidine ring in order to map the binding site at the 5-HT2A receptor.
LSZ has little to no history of human usage prior to 2012 when it appeared on some research chemical markets in the UK. LSZ later gained international popularity through a small cluster of mail-order novel psychedelic shops that appeared in 2012. There have also been several unconfirmed reports of LSZ being synthesized in illicit laboratories and distributed on blotter paper or in liquid solution under names such as "Diazedine" and "λ" (or "Lambda").
LSZ is not considered to be addictive or physiologically toxic. Nevertheless, adverse psychological reactions such as severe anxiety, paranoia and psychosis are always possible, particularly among those predisposed to mental illness. It is highly advised to use harm reduction practices if using this substance.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 References
LSZ, or d-lysergic acid 2,4-dimethylazetidide, is a semi-synthethic alkaloid of the lysergamide famiy. It contains a core structure of lysergic acid with an amine functional group bound to RN of the chemical structure. This core polycyclic structure is an indole derivative, and has tryptamine and phenethylamine groups embedded within it.
The structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (lysergic acid). At carbon 8 of the quinoline, an amide group is bound. Additionally, the substitutions of the terminal nitrogen atom of the amide group form a 2,4-dimethylazetidide group. LSZ is additionally substituted at carbon 6 with a methyl group.
There are three possible stereoisomers around the azetidine ring with the (S,S)-(+) isomer being the most active. It is slightly more potent than LSD itself in drug discrimination tests using trained rats.
LSZ likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from LSZ's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- Analysis enhancement
- Conceptual thinking
- Creativity enhancement
- Emotion enhancement
- Immersion enhancement
- Increased music appreciation
- Memory suppression
- Novelty enhancement
- Personal bias suppression
- Spirituality enhancement
- Thought acceleration
- Thought disorganization
- Thought loops
- Time distortion
- Unity and interconnectedness
Anecdotal reports which describe the effects of this compound within our experience index include:
Additional experience reports can be found here:
Toxicity and harm potential
This toxicity and harm potential section is a stub.
As such, it may contain incomplete or even dangerously wrong information. You can help by expanding or correcting it.
The toxicity and long-term health effects of recreational LSZ do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because LSZ is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried LSZ suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
LSZ is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of LSZ are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). LSZ presents cross-tolerance with all psychedelics, meaning that all psychedelics will have a reduced effect after the consumption of LSZ.
- Denmark: As of August 25th, 2015, LSZ is specifically named on the list of illegal substances in Denmark.
- Germany: LSZ is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- Latvia: LSZ is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1th, 2015.
- Sweden: Following its sale as a designer drug, LSZ was made illegal in Sweden on 26 January 2016.
- Switzerland: LSZ was added to the list of controlled substances on the 1st of December 2015.
- United Kingdom: As of January 7th, 2015, LSZ is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.
- Nichols, D.E., Frescas S., Marona-Lewicka D., and Kurrasch-Orbaugh D.M. (2002). Lysergamides of Isomeric 2,4-Dimethylazetidines Map the Binding Orientation of the Diethylamide Moiety in the Potent Hallucinogenic Agent N,N-Diethyllysergamide (LSD). Journal of Medicinal Chemistry 2002 45 (19), 4344-4349. DOI: 10.1021/jm020153s
- ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" | https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/318693/UpdateGenericDefinitionTryptamines.pdf
- The Drug Revolution That No One Can Stop | https://medium.com/matter/the-drug-revolution-that-no-one-can-stop-19f753fb15e0#.fupvbuawp
- Life Is a Cosmic Giggle on the Breath of the Universe | http://www.vice.com/en_ca/read/life-is-a-cosmic-giggle-803-v18n5?Contentpage=3
- Cole, Krystle (2005). Lysergic. Indianapolis: Dog Ear Publishing. ISBN 1-59858-007-8.
- Lüscher, C., & Ungless, M. A. (2006). The Mechanistic Classification of Addictive Drugs, 3(11). https://doi.org/10.1371/journal.pmed.0030437
- Nichols, D. E. (2016). "Psychedelics." Pharmacological Reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478
- Strassman, R. J. (1984). Adverse Reactions to Psychedelic Drugs: A Review of the Literature. The Journal of Nervous and Mental Disease, 172(10), 577-595. PMID: 6384428
- Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD) (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/12213075
- "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2.4.punkts) | http://likumi.lv/doc.php?id=121086
- (in Swedish) Folkhälsomyndigheten. | https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/januari/31-nya-substanser-klassas-som-narkotika-eller-halsofarlig-vara/
- ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014.